Therapeutic Solutions International Announces Immunological Mechanism of Action of StemVacs-V™ iPSC Derived Cancer Immunotherapeutic
Therapeutic Solutions International, Inc. (OTC Markets: TSOI) reported new data on its StemVacs-V product, which shows potential anticancer benefits by activating dual immunological mechanisms. In animal studies with B16 melanoma, treatment led to enhanced T cell responses and increased infiltration of macrophages and natural killer cells. The Company aims to advance StemVacs-V towards FDA filing, highlighting its capacity for large-scale production, customization for various cancers, and safety in preliminary studies.
- Demonstrated dual immunological mechanisms for anticancer activity.
- Increased T cell response and immune cell infiltration observed in animal studies.
- StemVacs-V shows promise for FDA approval and scalability.
- None.
ELK CITY, Idaho, March 22, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data demonstrating its StemVacs-V iPSC derived dendritic cell product stimulates two distinct immunological mechanisms responsible for its anticancer activity in animal studies.
In a series of experiments, Company scientists observed that mice bearing B16 melanoma treated with StemVacs-V possessed an increased T cell response towards the tumor associated antigen Brother of the Regulator of Imprinted Sites. Additionally, examination of tumors regressing as a result of StemVacs-V treatment, revealed increased macrophage and natural killer cell infiltration. Depletion of either T cells or natural killer cells in treated mice abrogated the cancer-reducing activity of StemVacs-V.
"As we advance our stem derived product towards FDA filing, it is critical to demonstrate not only reproducible efficacy but also distinct mechanisms of action" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "We are particularly excited by the dual mechanism of action displayed by StemVacs-V, suggesting possible advantages to other cancer therapies which usually only stimulate either adaptive or innate immunity."
"Although current immunotherapies such as checkpoint inhibitors have resulted in remissions in numerous types of advanced cancers, these approaches still fail to produce a meaningful response in tumors considered immunologically "cold"" said Famela Ramos, Vice President of Business Development for the Company. "Given that tumors which respond to checkpoint inhibitors are usually characterized by natural killer cell infiltration, we are currently exploring the possibility of utilizing StemVacs-V as a sensitizer for other FDA approved immunotherapies."
"We are extremely excited about the rapid rate our team is advancing the StemVacs-V product, which promises to be a type of immunotherapy that is: a) easy to produce in large quantities; b) can be tailored to specific biological characteristics of different cancers; and c) appears safe and highly potent in existing animal studies" said Timothy Dixon, President and CEO of the Company.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-announces-immunological-mechanism-of-action-of--stemvacs-v-ipsc-derived-cancer-immunotherapeutic-301252742.html
SOURCE Therapeutic Solutions International
FAQ
What is the significance of the new data on StemVacs-V by TSOI?
When is TSOI planning to file for FDA approval for StemVacs-V?
What types of cancer could benefit from StemVacs-V treatment?
How does StemVacs-V compare with existing immunotherapies?
What were the results of the animal studies conducted by TSOI?
